ProQR Therapeutics works on next generation medicines
Recently, the ownership of the Mibiton DNA analysing equipment was transferred to ProQR Therapeutics, a Dutch company working on next generation medicines. At the start of the Mibiton project (Q1 2013), only five people worked for ProQR Therapeutics. The company is now listed on the US technology stock exchange NASDAQ and 150 people are employed.
We interviewed CEO Daniel de Boer about the developments of his company, also illustrating the role of the Mibiton Foundation.